Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Recommendation of “Hold” by Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has been given a consensus rating of “Hold” by the seventeen analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $25.13.

Several brokerages recently issued reports on HIMS. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Morgan Stanley initiated coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Finally, Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the sale, the chief financial officer now owns 118,077 shares of the company’s stock, valued at $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the transaction, the insider now owns 193,980 shares in the company, valued at approximately $4,306,356. This trade represents a 3.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,080,208 shares of company stock worth $29,106,823. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Quarry LP increased its stake in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after acquiring an additional 2,913 shares during the last quarter. Finally, Amalgamated Bank increased its stake in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 1.1 %

Shares of Hims & Hers Health stock opened at $26.19 on Friday. The stock has a market cap of $5.72 billion, a P/E ratio of 59.52 and a beta of 1.31. Hims & Hers Health has a 12-month low of $8.14 and a 12-month high of $35.02. The business’s 50 day moving average is $27.42 and its 200-day moving average is $21.72.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the firm posted ($0.04) earnings per share. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.